Arcus Biosciences Inc
NYSE:RCUS

  • LAST PRICE
    17.9600
  • TODAY'S CHANGE (%)
    0.5400 (3.0999%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    17.4600 / 17.4200
  • Day Range
    17.1100
    18.0700
  • 52 Week Range
    13.5200
    20.3100
  • Volume
    541,813

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
RCUS
Arcus Biosciences Inc
1.6B
-5.7x
---
TVTX
Travere Therapeutics Inc
1.6B
-4.1x
---
NRIX
Nurix Therapeutics Inc
1.6B
-7.3x
---
ARVN
Arvinas Inc
1.7B
-4.7x
---
ARDX
Ardelyx Inc
1.2B
-17.1x
---
ARQT
Arcutis Biotherapeutics Inc
1.5B
-7.1x
---
As of 2024-12-12

Company Information

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Contact Information

Headquarters
3928 Point Eden WayHAYWARD, CA, United States 94545-3719
Phone
510-694-6200
Fax
302-730-1370

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Terry Rosen
President, Co-Founder
Juan Jaen
Chief Financial Officer
Robert Goeltz
Chief Operating Officer
Jennifer Jarrett
General Counsel
Carolyn Tang

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.6B
Revenue (TTM)
$263.0M
Shares Outstanding
91.5M
Arcus Biosciences Inc does not pay a dividend.
Beta
0.85
EPS
$-3.15
Book Value
$6.12
P/E Ratio
-5.7x
Price/Sales (TTM)
6.2
Price/Cash Flow (TTM)
---
Operating Margin
-120.91%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.